Fineline Cube

Follow:
14691 Articles
Dualitas Signs Research Collaboration and License Deal with Roche – Bispecific Antibody Partnership Valued at Up to US$1 Billion
CompanyDeals

Dualitas Signs Research Collaboration and License Deal with Roche – Bispecific Antibody Partnership Valued at Up to US$1 Billion

HitGen Co‑Invests in Connexus Therapeutics' Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing
CompanyDeals

HitGen Co‑Invests in Connexus Therapeutics’ Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

Haisco's HSK42360‑Na Proposed for CDE Breakthrough Therapy Designation – Next‑Generation BRAF Inhibitor Targets V600‑Mutant High‑Grade Glioma
CompanyDrug

Haisco’s HSK42360‑Na Proposed for CDE Breakthrough Therapy Designation – Next‑Generation BRAF Inhibitor Targets V600‑Mutant High‑Grade Glioma

Astellas' PADCEV Plus Keytruda Receives Positive CHMP Opinion – Perioperative Muscle‑Invasive Bladder Cancer Regimen Nears EU Approval
CompanyDrug

Astellas’ PADCEV Plus Keytruda Receives Positive CHMP Opinion – Perioperative Muscle‑Invasive Bladder Cancer Regimen Nears EU Approval

Novo Nordisk's FREHEMGO (Denecimig) Receives Positive CHMP Opinion – Next‑Generation Hemophilia A Prophylaxis Nears EU Authorization
CompanyDrug

Novo Nordisk’s FREHEMGO (Denecimig) Receives Positive CHMP Opinion – Next‑Generation Hemophilia A Prophylaxis Nears EU Authorization

Nutshell Therapeutics' NTS231 Clears FDA IND – First NRF2 Molecular Glue Degrader from China and Second Globally to Enter Clinical Development, Targeting KEAP1 to Block NRF2
CompanyDrug

Nutshell Therapeutics’ NTS231 Clears FDA IND – First NRF2 Molecular Glue Degrader from China and Second Globally to Enter Clinical Development, Targeting KEAP1 to Block NRF2

Simcere Pharmaceutical Files IND for SIM0688 – First B7‑H3/c‑Met Bispecific ADC to Enter Clinical Development
CompanyDrug

Simcere Pharmaceutical Files IND for SIM0688 – First B7‑H3/c‑Met Bispecific ADC to Enter Clinical Development

CDE Includes Beijing Toll Biotech's TollB‑001 Tablets in Rare Disease Pilot Scheme – Novel Oral TLR8 Inhibitor Targets Systemic Sclerosis with First Specific Treatment Potential
CompanyDrug

CDE Includes Beijing Toll Biotech’s TollB‑001 Tablets in Rare Disease Pilot Scheme – Novel Oral TLR8 Inhibitor Targets Systemic Sclerosis with First Specific Treatment Potential

CSPC Pharmaceutical Initiates Phase II Trial of SYH2069 – Novel Long‑Acting GLP‑1R/GIPR Dual Agonist with Dual‑Biased Activity for Adult Type 2 Diabetes
CompanyDrug

CSPC Pharmaceutical Initiates Phase II Trial of SYH2069 – Novel Long‑Acting GLP‑1R/GIPR Dual Agonist with Dual‑Biased Activity for Adult Type 2 Diabetes

GenScript Biotech Collaborates with Lilly TuneLab – Pairing Large‑Scale Wet‑Lab Validation with Eli Lilly's AI/ML Drug Discovery Platform
CompanyDeals

GenScript Biotech Collaborates with Lilly TuneLab – Pairing Large‑Scale Wet‑Lab Validation with Eli Lilly’s AI/ML Drug Discovery Platform

Novo Nordisk and Anthropic Announce AI Collaboration – Claude Science to Accelerate Drug Discovery and AI‑Driven Software Development
CompanyDeals

Novo Nordisk and Anthropic Announce AI Collaboration – Claude Science to Accelerate Drug Discovery and AI‑Driven Software Development

NMPA Grants Priority Review to Everest Medicines' Manufacturing‑Transfer NDA for VELSIPITY (Etrasimod) – Localizing Production of Its Approved Ulcerative Colitis Therapy in China
CompanyDrug

NMPA Grants Priority Review to Everest Medicines’ Manufacturing‑Transfer NDA for VELSIPITY (Etrasimod) – Localizing Production of Its Approved Ulcerative Colitis Therapy in China